Aadi Bioscience to Announce Q2 2024 Results and Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI), a company specializing in precision oncology, has announced it will hold a conference call and live webcast on August 7, 2024, at 8:30 am EDT (5:30 am PDT). The event will focus on discussing the company's financial results for the second quarter of 2024 and will also provide updates on recent corporate developments.

Participants who wish to join the live webcast can access it through the "Investors & News" section of the Aadi Bioscience website at aadibio.com. Those opting to join via telephone should register in advance through the provided Conference Registration link. Upon registration, participants will receive a confirmation email with the necessary details, including the dial-in number, a unique passcode, and a registrant ID. The conference call and webcast will be archived on the company's website for at least 30 days following the event.

Aadi Bioscience is a commercial-stage precision oncology firm dedicated to developing and marketing therapies targeting cancers with alterations in the mTOR pathway. The mTOR pathway is a crucial regulator of cell growth and cancer progression. Aadi uniquely combines nanoparticle albumin-bound (nab) technology with a potent mTOR inhibitor, sirolimus, to maximize the efficacy of mTOR inhibition. The company has received FDA approval for FYARRO®, which is used to treat adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

In addition to FYARRO®, Aadi is conducting multiple clinical trials to explore the potential of nab-sirolimus in various cancer types. One of these trials is PRECISION1, a Phase 2 tumor-agnostic registration-intended trial aimed at treating mTOR inhibitor-naïve malignant solid tumors that harbor TSC1 or TSC2 inactivating alterations. The company is also undertaking two other Phase 2 trials focused on challenging mTOR-driven cancers. These trials involve the investigation of nab-sirolimus in the treatment of neuroendocrine tumors (NETs) of the lung, gastrointestinal tract, and pancreas, as well as advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole.

Aadi Bioscience continues to push the boundaries in the field of precision oncology, aiming to provide effective treatments for patients with cancers exhibiting mTOR pathway alterations. Through its ongoing trials and the commercial success of FYARRO®, the company is positioning itself as a leader in the development and commercialization of innovative cancer therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!